… target for cancer therapy. It is expressed at high levels in a number of solid tumors, including
… In view of the fact that cisplatin/carboplatin and fluorouracil (FU) combination therapy is the …

… of cisplatin plus fluorouracil (5-FU) and carboplatin plus 5-FU versus single-agent methotrexate
(MTX) in patients with recurrent and metastatic squamous-cell carcinoma (SCC) of the …

… cell carcinoma (LA-HNSCC). However, around one-third of the patients cannot complete
cisplatin because of toxicity. Carboplatin plus 5-fluorouracil (carbo-5FU… carbo-5FU and cisplatin. …

… Carboplatin/5FU may be an alternative regimen without … of carboplatin/5FU regimen with
the cisplatin/5FU regimen. … with either cisplatin/5FU or carboplatin/5FU for metastatic and …

… cancer were entered into a phase I-II trial of carboplatin in combination with 5… carboplatin
trials suggest activity similar to cisplatin in patients with recurrent squamous-cell carcinoma of …

… A randomized trial was designed to compare cisplatin (CDDP) and fluorouracil (FU) versus
carboplatin (CBDCA) and FU as neoadjuvant treatment in stage IV-M0 head and neck cancer …

… carboplatin-5Fu with advanced head and neck carcinoma. Proceedings of the Fourth European
Conference in Clinical Oncology and Cancer … II trial with carboplatin/5Fu in previously …

… One patient of the CDDP/5FU group was excluded because treatment was terminated when
… patient chemotherapy with CDDP/5FU was switched to carboplatin alone after only one day …

Full article: Retrospective analysis of chronomodulated chemotherapy versus conventional
chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or …

… the US Cisplatin (100 mg/m 2 intravenously) or carboplatin (area under the curve 5
intravenously) on day 1 with 5‐fluorouracil (1,000 mg/m 2 /day continuous intravenous infusion days …